14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.72 $7.24 Wednesday, 24th Apr 2024 AFMD stock ended at $4.88. This is 8.79% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 11.72% from a day low at $4.87 to a day high of $5.44.
90 days $4.25 $7.24
52 weeks $2.24 $11.10

Historical Affimed N.V. prices

Date Open High Low Close Volume
Mar 22, 2022 $41.60 $43.75 $41.05 $43.00 98 501
Mar 21, 2022 $42.10 $42.40 $40.65 $41.20 71 719
Mar 18, 2022 $44.50 $44.75 $42.50 $42.80 153 138
Mar 17, 2022 $43.30 $45.30 $43.20 $44.60 106 550
Mar 16, 2022 $43.90 $44.30 $42.65 $43.80 90 490
Mar 15, 2022 $42.10 $43.20 $41.50 $43.10 57 690
Mar 14, 2022 $44.80 $44.80 $41.50 $42.10 96 310
Mar 11, 2022 $45.60 $46.50 $44.65 $44.70 94 350
Mar 10, 2022 $44.60 $45.40 $43.95 $45.20 54 670
Mar 09, 2022 $42.80 $45.90 $42.80 $45.40 123 300
Mar 08, 2022 $40.90 $43.10 $40.35 $41.70 80 990
Mar 07, 2022 $41.00 $42.20 $40.70 $41.10 83 430
Mar 04, 2022 $41.60 $42.80 $40.60 $40.90 46 310
Mar 03, 2022 $44.80 $45.10 $42.00 $42.40 80 420
Mar 02, 2022 $44.00 $45.20 $43.60 $44.80 61 710
Mar 01, 2022 $44.20 $45.00 $43.35 $43.90 95 560
Feb 28, 2022 $45.10 $45.70 $43.90 $44.10 121 200
Feb 25, 2022 $44.70 $45.90 $43.65 $45.90 112 540
Feb 24, 2022 $40.30 $44.60 $40.00 $44.40 130 250
Feb 23, 2022 $44.60 $44.60 $41.92 $42.20 104 170
Feb 22, 2022 $41.30 $43.35 $41.30 $42.30 100 750
Feb 18, 2022 $43.20 $43.70 $41.75 $42.20 72 340
Feb 17, 2022 $44.30 $44.60 $42.90 $43.60 91 120
Feb 16, 2022 $45.10 $45.80 $44.05 $45.00 61 590
Feb 15, 2022 $43.90 $46.65 $43.90 $45.50 110 190
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT